Top

International Journal of Clinical Oncology

Published in:

01-02-2010 | Case Report

Successful treatment for metastases from renal cell carcinoma with alternation of interferon-alpha subtypes

Authors: Sotaro Miwa, Yoshifumi Kadono, Toshiaki Sugata, Atsushi Mizokami, Mikio Namiki

Published in: International Journal of Clinical Oncology | Issue 1/2010

Abstract

Here we present a case in which alternation of interferon-alpha (IFN-α) treatments was effective in treating pulmonary metastases and lymph node metastases from renal cell carcinoma (RCC). A 56-year-old man underwent left radical nephrectomy under the diagnosis of left RCC. The histological diagnosis was clear cell carcinoma G2, IFN-α, pT1b. He subsequently underwent two operations for right pulmonary metastasis and right hilar lymph node metastasis. Postoperatively he was treated with intramuscular administration of natural IFN-α (Sumiferon) which prevented definite recurrence for 1 year. However, multiple pulmonary metastases and left hilar lymph node metastasis occurred 11 months after discontinuation of Sumiferon. Therefore, treatment with another natural IFN-α (OIF) was started. Although OIF was continued for 7 months, pulmonary metastases and left hilar lymph node metastasis continued to progress. Therefore, treatment was changed to Sumiferon, after which the pulmonary metastases and left hilar lymph node metastasis decreased in size. The metastases showed no progression for 16 months after switching from OIF to Sumiferon.

Cerfolio RJ, Allen MS, Deschamps C et al (1994) Pulmonary resection of metastatic renal cell carcinoma. Ann Thorac Surg 57:339–344PubMedCrossRef

Oya M, Asakura H, Mizuno R et al (2005) Repeated regression of pulmonary metastasis from renal cell carcinoma after treatment using different interferon-alpha preparations. Biomed Res 26:135–137CrossRefPubMed

Fujita K, Tanaka M, Kaneko T et al (2007) Pulmonary metastasis of renal cell carcinoma with different responses to two kinds of natural interferon-alpha (in Japanese). Rinsho Hinyokika 61:749–752

Kato Y, Saga Y, Hori J et al (2006) A case report of advanced renal cancer that showed different responses to the alternation of therapeutic cytokines (in Japanese). Jpn J Urol 97:598–601

Nishida S, Igarashi M, Tachiki H (2008) Two cases of metastatic renal cell carcinoma with long survival after changing the type of IFNα used for treatment (in Japanese). Rinsho Hinyokika 62:621–624

Horiguchi A, Uchida A (2004) Advanced renal cell carcinoma showing a different response to two types of interferon-alpha (in Japanese). Rinsho Hinyokika 95:50–53

Yanai Y, Horie S, Yamamoto K et al (2001) Characterization of the antitumor activities of IFN-alpha8 on renal cell carcinoma cells in vitro. J Interferon Cytokine Res 21:1129–1136CrossRefPubMed

Nakamura K, Yoshikawa K, Yamada Y et al (2006) Differential profiling analysis of proteins involved in anti-proliferative effect of interferon-α on renal cell carcinoma cell lines by protein biochip technology. Int J Oncol 28:965–970PubMed

Yamaoka T, Kojima S, Ichi S et al (1999) Biologic and binding activities of IFN-alpha subtypes in ACHN human renal cell carcinoma cells and Dudi Burkitt’s lymphoma cells. J Interferon Cytokine Res 19:1343–1349CrossRefPubMed

10.

Tatokoro M, Fujii Y, Kawakami S et al (2008) Favorable response to combination treatment of cimetidine, cyclooxygenase-2 inhibitor and renin-angiotensin system inhibitor in metastatic renal cell carcinoma: report of three cases. Int J Urol 15:848–850CrossRefPubMed

Title: Successful treatment for metastases from renal cell carcinoma with alternation of interferon-alpha subtypes
Authors: Sotaro Miwa
Yoshifumi Kadono
Toshiaki Sugata
Atsushi Mizokami
Mikio Namiki
Publication date: 01-02-2010
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 1/2010
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-009-0003-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2010

Erratum to: Thymic squamous cell carcinoma producing granulocyte colony-stimulating factor associated with a high serum level of interleukin 6

Prediction of high-grade squamous intraepithelial lesions using the modified Reid index

Quality of life after neck dissection: a multicenter longitudinal study by the Japanese Clinical Study Group on Standardization of Treatment for Lymph Node Metastasis of Head and Neck Cancer

Clinical significance of dihydropyrimidine dehydrogenase and thymidylate synthase expression in patients with pancreatic cancer

Update on the classification and nomenclature system for neck dissection: revisions proposed by the Japan Neck Dissection Study Group

A prospective open-label trial of gabapentin as an adjuvant analgesic with opioids for Japanese patients with neuropathic cancer pain

Keynote webinar | Spotlight on antibody–drug conjugates in cancer